This Single Injection Shrinks Tumours Across The Body, Leaves Some Patients Cancer-Free, New Study Shows

Last Updated:March 30, 2026, 11:27 IST

A breakthrough cancer study shows that targeting just one tumour can spark a full-body immune attack, shrinking cancers widely and completely eliminating them in some patients

A single tumour injection triggered a body-wide immune response, shrinking cancers and even eliminating them in some patients (Image-Canva)

Cancer immunotherapy has promised results yet often delivered modest outcomes, leaving patients and researchers uncertain. In groundbreaking research, a redesigned immunotherapy has shown striking early effects resulting in complete remission in two patients.

What The Study Says

According to a recent study published in Science Daily on March 16, 2026, an antibody was injected directly into the tumour, leading to tumour shrinkage in half of the patients and eliminating all signs in two, marking a rare early breakthrough.

In a small phase 1 trial of 12 patients with metastatic cancers, including melanoma, renal cell carcinoma, and aggressive breast cancers, not only did the injected tumours shrink, but distant tumours disappeared in some cases. This discovery hints at a systemic effect from a local treatment, opening a new frontier in cancer therapy.

Single Tumour Injection Influences Whole-Body Response

Research tested a redesigned CD40 agonist antibody known as 2141-V11 by injecting it directly into a single tumour rather than administering it through the bloodstream. The results were remarkable; the tumours shrank in six patients, and two experienced complete remission, meaning their cancers disappeared entirely.

Surprisingly, non-injected tumours in these patients also regressed, suggesting that the therapy could trigger a body-wide immune attack on cancer cells. “Seeing these significant shrinkages and even complete remission in such a small subset of patients is quite remarkable,” said Juan Osorio, first author of the study and medical oncologist at Memorial Sloan Kettering Cancer Centre.

New Antibody Unlocks The Immune System

Researchers have studied CD40 agonist antibodies for more than two decades. These drugs target the CD40 receptor, present on the surface of certain immune cells, activating pathways that promote anti-tumour immunity. Early clinical trials, however, were disappointing.

While laboratory results were promising, patients suffered serious side effects, including widespread inflammation, liver damage, and dangerously low platelet counts, even at low doses.

In 2018, Jeffrey V. Ravetch and his team at Rockefeller University redesigned the antibody to enhance its effectiveness while minimising toxicity. By engineering 2141-V11 to improve binding and crosslinking with a specific Fc receptor, the antibody could more efficiently activate immune cells against tumours without causing severe systemic reactions.

Laboratory experiments using specially engineered mice had suggested that targeted delivery could dramatically improve safety and efficacy. Rather than injecting the drug into the bloodstream, researchers delivered it directly into tumours.

This approach reduced side effects and appeared to stimulate immunity against cancer. “When we did that, we saw only mild toxicity,” Ravetch explained.

Tumour Vanished As The Immune System Reacted

During the research, the experiences of two patients highlighted the treatment’s potential. One patient with metastatic melanoma had dozens of tumours across her leg and foot.

Doctors injected only a single tumour on her thigh, yet over successive treatments, all tumours disappeared. Similarly, a patient with metastatic breast cancer saw all tumours vanish, including those in her liver, lungs, and skin, after only the skin tumour was injected.

Samples from non-injected tumours also revealed TLS, confirming that the immune system was mobilised to distant sites. “Once the immune system identifies the cancer cells, immune cells migrate to the non-injected tumour sites,” Osorio explained.

Larger Trials And Future Implications

Encouraged by early results, Ravetch’s team has expanded trials to include nearly 200 patients across Memorial Sloan Kettering, Duke University, and Rockefeller University. The phase 1 and 2 studies aim to determine which patients are more likely to respond and how best to optimise dosing and delivery.

The observations from the initial trials highlight that patients who achieved complete remission had high levels of T-cell proliferation at the start of the trial, suggesting preexisting immune readiness may be crucial for treatment expansion.

Understanding these factors could enable researchers to predict responders and refine the therapy for broader use. “As a general rule, only 25 to 30% of patients respond to immunotherapy,” Ravetch noted. “The biggest challenge is identifying indicators of response and figuring out how to convert non-responders into responders.”

A Redesigned Edge For Cancer Treatment

The results of this trial suggest that direct tumour injection of a redesigned CD40 agonist antibody could overcome many limitations that have plagued previous immunotherapies.

Unlike systemic treatments that risk widespread toxicity, localised injection leverages the tumour itself to train the immune system, potentially inducing whole-body effects.

Instead of flooding the body with antibodies or drugs, this renewed approach to treating cancer focuses on intervention at one site that can trigger a cascade of immune activity with far-reaching effects. It also reinforces the critical role of immune microenvironments in determining therapeutic outcomes.

Cautious Optimism In The Medical Community

While growing evidence of cancer treatment offers hope, researchers caution that these early findings remain preliminary and based on a small trial. Larger, controlled studies are essential to verify efficacy, understand mechanisms, and determine which cancers and patients are most likely to benefit.

“The fact that a local injection can cause tumours elsewhere in the body to disappear is extraordinary,” Ravetch said. “It’s another dramatic and unexpected result from our trial.”

As the trials expand, scientists hope to refine this approach, enhance response rates, and reduce variability in patient outcomes. Combining the engineered CD40 antibody with other immunotherapies or conventional treatments may further improve efficacy.

For now, the research represents a cautious but thrilling step toward transforming treatment for patients with metastatic and otherwise hard-to-treat cancers.

According to a recent study published in Science Daily on March 16, 2026, an antibody was injected directly into the tumour, leading to tumour shrinkage in half of the patients and eliminating all signs in two, marking a rare early breakthrough.

In a small phase 1 trial of 12 patients with metastatic cancers, including melanoma, renal cell carcinoma, and aggressive breast cancers, not only did the injected tumours shrink, but distant tumours disappeared in some cases. This discovery hints at a systemic effect from a local treatment, opening a new frontier in cancer therapy.

Single Tumour Injection Influences Whole-Body Response

Research tested a redesigned CD40 agonist antibody known as 2141-V11 by injecting it directly into a single tumour rather than administering it through the bloodstream. The results were remarkable; the tumours shrank in six patients, and two experienced complete remission, meaning their cancers disappeared entirely.

Surprisingly, non-injected tumours in these patients also regressed, suggesting that the therapy could trigger a body-wide immune attack on cancer cells. “Seeing these significant shrinkages and even complete remission in such a small subset of patients is quite remarkable,” said Juan Osorio, first author of the study and medical oncologist at Memorial Sloan Kettering Cancer Centre.

New Antibody Unlocks The Immune System

Researchers have studied CD40 agonist antibodies for more than two decades. These drugs target the CD40 receptor, present on the surface of certain immune cells, activating pathways that promote anti-tumour immunity. Early clinical trials, however, were disappointing.

While laboratory results were promising, patients suffered serious side effects, including widespread inflammation, liver damage, and dangerously low platelet counts, even at low doses.

In 2018, Jeffrey V. Ravetch and his team at Rockefeller University redesigned the antibody to enhance its effectiveness while minimising toxicity. By engineering 2141-V11 to improve binding and crosslinking with a specific Fc receptor, the antibody could more efficiently activate immune cells against tumours without causing severe systemic reactions.

Laboratory experiments using specially engineered mice had suggested that targeted delivery could dramatically improve safety and efficacy. Rather than injecting the drug into the bloodstream, researchers delivered it directly into tumours.

This approach reduced side effects and appeared to stimulate immunity against cancer. “When we did that, we saw only mild toxicity,” Ravetch explained.

Tumour Vanished As The Immune System Reacted

During the research, the experiences of two patients highlighted the treatment’s potential. One patient with metastatic melanoma had dozens of tumours across her leg and foot.

Doctors injected only a single tumour on her thigh, yet over successive treatments, all tumours disappeared. Similarly, a patient with metastatic breast cancer saw all tumours vanish, including those in her liver, lungs, and skin, after only the skin tumour was injected.

Samples from non-injected tumours also revealed TLS, confirming that the immune system was mobilised to distant sites. “Once the immune system identifies the cancer cells, immune cells migrate to the non-injected tumour sites,” Osorio explained.

Larger Trials And Future Implications

Encouraged by early results, Ravetch’s team has expanded trials to include nearly 200 patients across Memorial Sloan Kettering, Duke University, and Rockefeller University. The phase 1 and 2 studies aim to determine which patients are more likely to respond and how best to optimise dosing and delivery.

The observations from the initial trials highlight that patients who achieved complete remission had high levels of T-cell proliferation at the start of the trial, suggesting preexisting immune readiness may be crucial for treatment expansion.

Understanding these factors could enable researchers to predict responders and refine the therapy for broader use. “As a general rule, only 25 to 30% of patients respond to immunotherapy,” Ravetch noted. “The biggest challenge is identifying indicators of response and figuring out how to convert non-responders into responders.”

A Redesigned Edge For Cancer Treatment

The results of this trial suggest that direct tumour injection of a redesigned CD40 agonist antibody could overcome many limitations that have plagued previous immunotherapies.

Unlike systemic treatments that risk widespread toxicity, localised injection leverages the tumour itself to train the immune system, potentially inducing whole-body effects.

Instead of flooding the body with antibodies or drugs, this renewed approach to treating cancer focuses on intervention at one site that can trigger a cascade of immune activity with far-reaching effects. It also reinforces the critical role of immune microenvironments in determining therapeutic outcomes.

Cautious Optimism In The Medical Community

While growing evidence of cancer treatment offers hope, researchers caution that these early findings remain preliminary and based on a small trial. Larger, controlled studies are essential to verify efficacy, understand mechanisms, and determine which cancers and patients are most likely to benefit.

“The fact that a local injection can cause tumours elsewhere in the body to disappear is extraordinary,” Ravetch said. “It’s another dramatic and unexpected result from our trial.”

As the trials expand, scientists hope to refine this approach, enhance response rates, and reduce variability in patient outcomes. Combining the engineered CD40 antibody with other immunotherapies or conventional treatments may further improve efficacy.

For now, the research represents a cautious but thrilling step toward transforming treatment for patients with metastatic and otherwise hard-to-treat cancers.

Stay Ahead, Read Faster

Scan the QR code to download the News18 app and enjoy a seamless news experience anytime, anywhere.

login